Iterum Therapeutics
About Iterum Therapeutics
Iterum Therapeutics Limited: Headquartered in Dublin, Ireland, we are a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.We are pursuing a balanced development strategy with multiple opportunities intended to treat the organisms responsible for many serious infections, which the Centers for Disease Control (CDC) has determined to be inadequately addressed by current therapies1.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Corey N. Fishman
CSO: Michael Dunne, MD
CFO: Judith M. Matthews
VP, Operations: Benjamin M. PE
VP, Development: Sailaja Puttagunta, MD
VP, Business Development & Supply Chain: John J. White
CAREER:
Please click here for Iterum Therapeutics' job opportunities.
101 articles with Iterum Therapeutics
-
Iterum Therapeutics Reports Third Quarter 2022 Financial Results
11/10/2022
Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the third quarter ended September 30, 2022.
-
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
11/3/2022
Iterum Therapeutics plc announced that the Company will release its third quarter 2022 financial results before the open of the U.S. financial markets on Thursday, November 10, 2022.
-
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
10/20/2022
Iterum Therapeutics plc today announced that the first patient has been dosed in its Phase 3 clinical trial, known as REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales (REASSURE).
-
Iterum Therapeutics to Present Data at IDWeek 2022
10/17/2022
Iterum Therapeutics plc announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2022.
-
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem
9/19/2022
Iterum Therapeutics plc today announced the United States Patent and Trademark Office has issued the Company a Notice of Allowance for U.S. patent application number 16/972,300.
-
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
Iterum Therapeutics plc announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm on Wednesday, September 14, 2022.
-
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule - Sep 01, 2022
9/1/2022
Iterum Therapeutics plc announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
-
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
8/17/2022
Iterum Therapeutics plc announced that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on August 18, 2022.
-
Kyowa Kirin announced it is dropping its Parkinson’s disease candidate, KW-6356, a follow-up to Nourianz, despite promising Phase II data that showed the drug is "potentially effective."
-
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA
7/11/2022
Iterum Therapeutics plc announced today that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) under the special protocol assessment (“SPA”) process on the design, endpoints and statistical analysis of a Phase 3 clinical trial for oral sulopenem etzadroxil-probenecid (“oral sulopenem”) for the treatment of uncomplicated urinary tract infections (“uUTI”).
-
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2022
7/6/2022
Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that it has granted a non-statutory share option to purchase an aggregate of 10,000 ordinary shares of the Company as an inducement to a newly hired employee.
-
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 14, 2022
6/14/2022
Iterum Therapeutics plc announced that it has granted a non-statutory share option to purchase an aggregate of 35,000 ordinary shares of the Company as an inducement to a newly hired employee.
-
Iterum Therapeutics Reports First Quarter 2022 Financial Results
5/13/2022
Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2022.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Iterum Therapeutics Provides Regulatory Update - May 11, 2022
5/11/2022
Iterum Therapeutics plc announced it met with the US Food and Drug Administration on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company’s new drug application for oral sulopenem etzadroxil-probenecid for the treatment of uncomplicated urinary tract infections.
-
Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
4/25/2022
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), today announced two poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 23-26, 2022 in Lisbon, Portugal.
-
Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
3/28/2022
Iterum Therapeutics plc today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
3/21/2022
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Monday, March 28, 2022
-
Iterum Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
3/10/2022
Iterum Therapeutics plc announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550.
-
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 08, 2022
2/8/2022
Iterum Therapeutics plc announced that it has granted a non-statutory share option to purchase an aggregate of 50,000 ordinary shares of the Company as an inducement to a newly hired employee.